Hi all, thanks for doing this. Liquid biopsies seem to be very effective at determining probability of recurrence when samples can be referenced to observed tumor mutations. How does this work with no patient matched tumor genome?
Also, the prevalence of ovarian cancer is relatively low among the general population, which I imagine makes the test more difficult. A test of high sensitivity (>95%) would still lead to many false positives. Is this a concern?
cwalker2300 t1_izeofbb wrote
Reply to We’re Sadeka Nujhat, Hannah Leese and Sandhya Moise from the Department of Chemical Engineering at the University of Bath in the United Kingdom. We research ways to detect cancer as early as possible to help save lives. by UniversityofBath
Hi all, thanks for doing this. Liquid biopsies seem to be very effective at determining probability of recurrence when samples can be referenced to observed tumor mutations. How does this work with no patient matched tumor genome?
Also, the prevalence of ovarian cancer is relatively low among the general population, which I imagine makes the test more difficult. A test of high sensitivity (>95%) would still lead to many false positives. Is this a concern?